Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial

Yi Xia(Wuhan University), Wei Xu(Second Military Medical University), Maogui Hu(Anhui Provincial Hospital), Hao-Rui Shen(Nanjing Medical University), Huayuan Zhu(Jiangsu Province Hospital), Kaiyang Ding(Anhui Provincial Hospital), Ruize Chen(Jiangsu Province Hospital), Yue Li(Southwest Petroleum University), Jianyong Li(Jiangsu Province Hospital), Jia‐Zhu Wu(Augusta University Health), Jin‐Hua Liang(Broad Institute), Li Wang(University of Science and Technology of China), Hua Yin(Yunnan University of Traditional Chinese Medicine)
Chinese Medical Journal
April 7, 2023
10.1097/cm9.0000000000002636
Cited by 7

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|238
Circular RNA circRNA_15698 aggravates the extracellular matrix of diabetic nephropathy mesangial cells via miR‐185/TGF‐β1
|Journal of Cellular Physiology|2018|172